Edotecarin

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameEdotecarin
Drug Alias Name埃多卡林edotecarinum艾特咔林edotecarinaPHA-782615 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisStomach Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm MetastasisStomach Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG